Patents Assigned to SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D
  • Patent number: 11696937
    Abstract: The present invention discloses glycopeptide compounds having activity of resisting drug-resistant bacteria, conforming to glycopeptide compounds represented by general formula (I), The present invention also provides a preparation method for and an application of the glycopeptide compounds. Upon testing, compared with a second-generation glycopeptide drug oritavancin, the glycopeptide antibiotic compounds have higher inhibition activity on drug-resistant bacterial strains, especially MRSA or VRE. Further testing shows that most of the glycopeptide compounds have safety higher than that of oritavancin and can be prepared into drugs for treating or preventing diseases caused by various bacterial infections, such as skin and soft tissue infections, meningitis, sepsis, pneumonia, arthritis, peritonitis, bronchitis, and empyema.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: July 11, 2023
    Assignees: Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd., Zhejiang Medicine Co., Ltd.
    Inventors: Chang Shao, Mei Ge, Lingao Ruan, Wei Wei, Xing Xia, Min Rao, Qingqian Meng, Minyu Luo
  • Publication number: 20140018303
    Abstract: The present invention relates to a novel compound, 3-amino-2-hydroxy-4-phenylbutanoyl-valyl-isoleucine with structure showed below. The compound is prepared from fermentation culture Streptomyces parvus CGMCC No. 4027 and is active as inhibitor of aminopeptidase. It can be used for preparation of aminopeptidase inhibitor.
    Type: Application
    Filed: November 16, 2011
    Publication date: January 16, 2014
    Applicant: SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D
    Inventors: Min Rao, Mei Ge, Minyu Luo, Lijun Ruan, Xing Xia, Li Zhu, Lingao Ruan, Huaixia Kang, Tian Yang, Tianjiao Wang, Qiushuang Li, Hanyan Jiang